Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232699 | 1.00 | CTSC (0.60) | CTSCITGB3ITGA2BLMNAMME | |
| SCHEMBL4432590 | 1.00 | CTSC (0.60) | CTSCITGB3ITGA2BLMNAMME | |
| Water SCHEMBL28030234 | 0.98 | CTSC (0.63) | CTSCITGB3ITGA2BLMNAMME | |
| Water SCHEMBL28030233 | 0.98 | CTSC (0.63) | CTSCITGB3ITGA2BLMNAMME | |
| Hydrochloric Acid SCHEMBL9501928 | 0.98 | CTSC (0.59) | CTSCITGB3ITGA2BLMNAMME | |
| Hydrochloric Acid SCHEMBL3634876 | 0.98 | CTSC (0.59) | CTSCITGB3ITGA2BLMNAMME | |
| Bromide SCHEMBL11242978 | 0.98 | CTSC (0.59) | CTSCITGB3ITGA2BLMNAMME | |
| Bromide SCHEMBL11242976 | 0.98 | CTSC (0.59) | CTSCITGB3ITGA2BLMNAMME | |
| SCHEMBL8068326 | 0.94 | MME (0.61) | CTSCITGB3ITGA2BLMNAMME | |
| SCHEMBL8068319 | 0.94 | MME (0.61) | CTSCITGB3ITGA2BLMNAMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534510-B2 | Peptide-receptive MHC-I complex compositions and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-27 | — | — | US | claimed |
| EP-3817757-B1 | PEPTIDE DEFICIENT-MHC CLASS I/CHAPERONE COMPOSITIONS AND METHODS | UNIV CALIFORNIA (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4136098-B1 | PEPTIDE-RECEPTIVE MHC-I COMPLEX COMPOSITIONS AND METHODS FOR THEIR GENERATION | UNIV CALIFORNIA (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| CN-118703593-A | Argininase quantitative detection kit, argininase qualitative detection kit and use method thereof | 武汉简为医疗科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240294601-A1 | PEPTIDE DEFICIENT-MHC CLASS I/CHAPERONE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNA | 2024-09-05 | — | — | US | claimed |
| CN-118384255-A | Application of walnut peptide in preparation of obesity improving medicine | 云南中医药大学 | 2024-07-26 | — | — | CN | claimed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | claimed |
| CN-117269494-A | A group of metabolic markers for breast cancer lung metastasis | 厦门大学 | 2023-12-22 | — | — | CN | claimed |
| US-11814420-B2 | Peptide deficient-MHC class I/chaperone compositions and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-14 | — | — | US | claimed |
| US-5430133-A | Semi-synthetic glycosaminoglycans with heparin or heparan structure of α-L-iduronic-2-O-sulfate acid modified in position 2 | ALFA WASSERMANN S.P.A. (IT) | 1995-07-04 | — | — | US | claimed |
| US-5410039-A | Process for the synthesis of glycosaminoglycans containing α-L-galacturonic acid substituted with nucleophilic groups in position 3 | ALFA WASSERMANN S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-5405949-A | Process for the synthesis of glycosaminoglycans with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid | ALFA WASSERNANN S.P.A. (IT) | 1995-04-11 | — | — | US | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534510-B2 | Peptide-receptive MHC-I complex compositions and methods | MICA, TAP2, TAP1 | CTSC 818/4885ITGB3 1089/4885ITGA2B 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.